The level of insider selling is trivial — less than 0.01% of market cap — and typical around earnings or option vesting events. No meaningful signal; traders should focus on the upcoming Phase 2 LOTUS trial data in Q2 2026 as the key catalyst.
Price Chart
Executive Summary
Two C-suite executives at Avalo Therapeutics — the CFO and CMO — sold a combined $19K in open-market transactions within a 7-day window, shortly after the company's 2025 earnings release. These sales follow routine stock option exercises and tax withholdings by insiders, including the CEO, which generated no cash proceeds. The total dollar value of open-market selling is minimal relative to the company's $405M market cap.
Key Financial Metrics
Key Facts
- CFO Christopher Sullivan sold 500 shares for $7,929 on 2026-04-01
- CMO Mittie Doyle sold 679 shares for $10,864 on 2026-04-01
- Total open-market selling by insiders: $18,793
- Multiple non-cash transactions occurred, including option exercises and tax-related share surrenders, with no economic value
- CEO Neil exercised options and surrendered 21,892 shares for tax withholding worth $304K, but this was not an open-market sale
Financial Impact
$18,793 in net open-market selling by insiders
Risk Factors
- Perception risk if investors misinterpret tax-related share surrenders as open-market selling
- Downside risk tied to clinical trial results, not insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-AVTX-1775243721239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access